相关实验视频

Updated: Jun 27, 2025

Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice

Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice

Published on: February 20, 2019

关于治疗动脉样硬化的表观遗传基因药物治疗的最新更新

Eko Fuji Ariyanto¹, Ibnu Wijaya², Zaky Alif Pradian²

¹Department of Biomedical Sciences, Faculty of Medicine, Universitas Padjadjaran, Sumedang, Indonesia.

Diabetes, metabolic syndrome and obesity : targets and therapy

|May 6, 2024

概括

诸如DNA甲基化和非编码RNA等表观遗传修饰在动脉样硬化中发挥关键作用,这是心血管疾病的主要原因. 本综述探讨了针对这些表观遗传变化的新药,用于治疗动脉样硬化.

科学领域:

心血管生物学心血管生物学
分子医学是分子医学.
表观遗传学在表观遗传学中,表观遗传学是指表观遗传学.

背景情况:

动脉样硬化是全球死亡的主要原因,涉及动脉胆固醇积累和慢性炎症.
它是严重的心血管疾病 (CVD) 的基础,如心肌梗塞和中风.
表观遗传机制,包括DNA甲基化,基因组修饰和非编码RNA (ncRNA),越来越被认为是动脉生成的关键调节者.

研究的目的:

审查最近在开发新型动脉样硬化治疗中取得的进展.
专注于针对疾病过程中涉及的表观遗传修饰的药物.

主要方法:

对最近关于动脉样硬化的表观遗传调制研究的文献综述.
针对DNA甲基化,基因素修饰和ncRNAs的治疗策略的分析.

主要成果:

表观遗传失调显著导致动脉样硬化的发展和进展.
新兴的治疗策略旨在逆转或抵消这些表观遗传变化.
药物开发的重点是调节特定的表观遗传通路,以对抗心血管疾病.

结论:

表观遗传修饰是新型动脉样硬化治疗的有希望的目标.
向DNA甲基化,基因组修饰和ncRNAs为创新的心血管疾病疗法提供了潜力.
对这些表观遗传机制的进一步研究可能会导致针对动脉样硬化的更有效的干预措施.

关键词:

通过DNA甲基化.动脉样硬化动脉样硬化基质子的修改基质子的修改没有编码的RNAs.药物治疗药物治疗

更多相关视频

Quantitative Analysis and Characterization of Atherosclerotic Lesions in the Murine Aortic Sinus

Quantitative Analysis and Characterization of Atherosclerotic Lesions in the Murine Aortic Sinus

Published on: December 7, 2013

Quantification of Atherosclerosis in Mice

Quantification of Atherosclerosis in Mice

Published on: June 12, 2019

相关概念视频

Epigenetic Regulation

Epigenetic Regulation

Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...